Senti Biosciences Holdings

Closed (deSPAC)

Profile in progress

What it is: SENTI-202 is intended to treat AML, employs an OR Logic Gate and a NOT Logic Gate gene circuit to selectively kill cancer cells with broader spectrum activity while sparing healthy cells, and is also Multi-Armed with calibrated release interleukin-15 (crIL-15) to promote NK cell persistence and tumor killing
What it’s doing now: Merging with Senti Biosciences Holdings, Inc. (DYNS) — closed (despac).
What you should know: The deal carries a $200M minimum-cash condition — heavy redemptions can break it.

The business, per its filings

SEC primary

SENTI-202 is intended to treat AML, employs an OR Logic Gate and a NOT Logic Gate gene circuit to selectively kill cancer cells with broader spectrum activity while sparing healthy cells, and is also Multi-Armed with calibrated release interleukin-15 (crIL-15) to promote NK cell persistence and tumor killing. • OR GATE: Bivalent FLT3 OR CD33 Logic Gated activating CAR (aCAR) is engineered to increase AML leukemic stem cell (LSC) and blast clearance by targeting cancer cells expressing FLT3, CD33, or both, thus reducing single antigen tumor escape, and potentially providing deeper and longer remissions. • NOT GATE: Endomucin (EMCN) NOT Logic Gated inhibitory CAR (iCAR) is engineered to protect healthy hematopoietic stem cells that are EMCN positive (EMCN+) from off-tumor toxicity, potentially increasing therapeutic specificity and improving post-treatment regeneration of a healthy hematopoietic system. • Calibrated release interleukin-15: The crIL-15 construct is designed to simultaneously produce both membrane-associated and fully secreted IL-15, enabling both autocrine signaling (to increase CAR-NK cell proliferation and persistence) and paracrine signaling (to stimulate the patient's surrounding immune cells).

What the company says about itself

Web research — not audited

What our web check found

[WEB-INTEL 2026-08-26] 1 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Payments of up to $60 Million" [https://investors.sentibio.com/news-releases/news-release-details/senti-biosciences-holdings-inc-announces-strategic-transaction] [WEB-INTEL 2026-08-26] 4 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Payments of up to $60 Million" [https://investors.sentibio.com/news-releases/news-release-details/senti-biosciences-holdings-inc-announces-strategic-transaction] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "$10 million upon filing and acceptance of a Biologics License Application (BLA) for SENTI-202" [https://www.globenewswire.com/news-release/2026/07/15/3327605/0/en/senti-biosciences-holdings-inc-announces-a-strategic-transaction-to-unlock-value-for-its-gene-circuit-enabled-pipeline-including-senti-202-and-to-sharpen-its-focus-on-next-generati.html] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "$20 million upon FDA approval of a BLA for SENTI-202" [https://www.globenewswire.com/news-release/2026/07/15/3327605/0/en/senti-biosciences-holdings-inc-announces-a-strategic-transaction-to-unlock-value-for-its-gene-circuit-enabled-pipeline-including-senti-202-and-to-sharpen-its-focus-on-next-generati.html] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "$30 million upon achievement of $200 million in cumulative net sales of SENTI-202" [https://www.globenewswire.com/news-release/2026/07/15/3327605/0/en/senti-biosciences-holdings-inc-announces-a-strategic-transaction-to-unlock-value-for-its-gene-circuit-enabled-pipeline-including-senti-202-and-to-sharpen-its-focus-on-next-generati.html]

Source: company web presence · marketing claims are reported as claims, never merged into the filed figures above.

The deal it’s entering

Senti Biosciences Holdings is merging with Senti Biosciences Holdings, Inc. (DYNS) currently marked Closed (deSPAC).

Headline equity value	—
Minimum cash to close	$200M

Structure per SEC accession(s) 0001193125-22-041549. How to read these numbers: headline vs effective valuation · what a definitive agreement commits

What exactly is being valued, and at what

Common questions

Is Senti Biosciences Holdings going public?

Senti Biosciences Holdings has an approved merger with the SPAC Senti Biosciences Holdings, Inc. (DYNS). Deal status: Closed (deSPAC).

Does Senti Biosciences Holdings have revenue?

The filings we've parsed don't state a usable revenue figure yet; this profile is updated as new documents land.

Educational content, not investment advice.